In Exelixis, Inc. v. MSN Laboratories Private Ltd., No. 2025-1236 (Fed. Cir. Aug. 31, 2026), the Federal Circuit affirmed that claims to a genus of crystalline salt forms of a drug compound were adequately supported under the written description requirement, even though the specification specifically described only two polymorphs.
Exelixis owns a number of patents covering its cancer drug Cabometyx®, whose active ingredient is cabozantinib (L)-malate (the “Malate Salt Patents”). The Malate Salt Patents claim the genus of crystalline cabozantinib (L)-malate salts. However, the specification only specifically describes two polymorphs, N-1 and N-2. When MSN filed an abbreviated new drug application (ANDA) for generic cabozantinib (L)-malate tablets using a different polymorph, form S, Exelixis sued for infringement. The district court found that MSN infringed the Malate Salt Patents and rejected MSN’s written description defense, holding that the specification’s disclosure of the